Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

30-36. (canceled)

37. (previously presented) A method of effectively treating pain in humans or other mammals, comprising administering to a patient an analgesic combination consisting essentially of 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof such that the dosing interval of the 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

38. (previously presented) The method of claim 37, wherein the 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof; and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered orally.

39. (previously presented) The method of claim 37, wherein the 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered in a single oral dosage form.

40. (previously presented) The method of claim 37, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof would be sub-therapeutic if administered without the 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof.

41. (previously presented) The method of claim 37, wherein the 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof is administered before, simultaneously with, or after administration of the oxycodone and/or at least one pharmaceutically acceptable salt thereof, such that the dosing interval of the 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

42. (previously presented) A method of reducing the oxycodone and/or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain, comprising co-administering said oxycodone and/or at least one pharmaceutically acceptable salt thereof with 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said oxycodone and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said oxycodone and/or at least one pharmaceutically acceptable salts thereof.

43. (previously presented) A method of reducing the amount of 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain comprising co-administering said 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof with an effective amount of oxycodone and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said 5-(4-fluorophenyl)-1-[4-methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof.

44. (canceled)

45. (previously presented) The method of claim 37, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.